The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C
Hepatitis C virus (HCV) affects approximately 268,000 Canadians and results in more years of life lost than any other infectious disease in the country. Both the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2016/7603526 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567508879540224 |
|---|---|
| author | Nicholas van Buuren Lorraine Fradette Jason Grebely Alexandra King Mel Krajden Sonya A. MacParland Alison Marshall Sahar Saeed Joyce Wilson Marina B. Klein Selena M. Sagan |
| author_facet | Nicholas van Buuren Lorraine Fradette Jason Grebely Alexandra King Mel Krajden Sonya A. MacParland Alison Marshall Sahar Saeed Joyce Wilson Marina B. Klein Selena M. Sagan |
| author_sort | Nicholas van Buuren |
| collection | DOAJ |
| description | Hepatitis C virus (HCV) affects approximately 268,000 Canadians and results in more years of life lost than any other infectious disease in the country. Both the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a priority and supported the establishment of a National Hepatitis C Research Network. In 2015, the introduction of new interferon- (IFN-) free therapies with high cure rates (>90%) and few side effects revolutionized HCV therapy. However, a considerable proportion of the population remains undiagnosed and treatment uptake remains low in Canada due to financial, geographical, cultural, and social barriers. Comprehensive prevention strategies, including enhanced harm reduction, broader screening, widespread treatment, and vaccine development, are far from being realized. The theme of the 2016 symposium, “We’re not done yet: remaining challenges in Hepatitis C,” was focused on identifying strategies to enhance prevention, diagnosis, and treatment of HCV to reduce disease burden and ultimately eliminate HCV in Canada. |
| format | Article |
| id | doaj-art-444083c0ca1e403ba5aa243cf46c6c9e |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-444083c0ca1e403ba5aa243cf46c6c9e2025-02-03T01:01:22ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972016-01-01201610.1155/2016/76035267603526The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis CNicholas van Buuren0Lorraine Fradette1Jason Grebely2Alexandra King3Mel Krajden4Sonya A. MacParland5Alison Marshall6Sahar Saeed7Joyce Wilson8Marina B. Klein9Selena M. Sagan10Department of Genetics, Stanford University School of Medicine, Stanford, CA, USACentre de Recherche du Centre Hospitalier Universitaire de Montréal (CHUM), Montreal, QC, CanadaThe Kirby Institute, UNSW, Sydney, NSW 2052, AustraliaSimon Fraser University, Burnaby, BC, CanadaBritish Columbia Centre for Disease Control, Vancouver, BC, V5Z 4R4, CanadaMulti-Organ Transplant Program, University Health Network, University of Toronto, Toronto, ON, CanadaThe Kirby Institute, UNSW, Sydney, NSW 2052, AustraliaChronic Viral Illnesses Service, Division of Infectious Diseases and Research Institute of the McGill University Health Centre, Montreal, QC, CanadaDepartment of Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK, CanadaChronic Viral Illnesses Service, Division of Infectious Diseases and Research Institute of the McGill University Health Centre, Montreal, QC, CanadaDepartment of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, CanadaHepatitis C virus (HCV) affects approximately 268,000 Canadians and results in more years of life lost than any other infectious disease in the country. Both the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a priority and supported the establishment of a National Hepatitis C Research Network. In 2015, the introduction of new interferon- (IFN-) free therapies with high cure rates (>90%) and few side effects revolutionized HCV therapy. However, a considerable proportion of the population remains undiagnosed and treatment uptake remains low in Canada due to financial, geographical, cultural, and social barriers. Comprehensive prevention strategies, including enhanced harm reduction, broader screening, widespread treatment, and vaccine development, are far from being realized. The theme of the 2016 symposium, “We’re not done yet: remaining challenges in Hepatitis C,” was focused on identifying strategies to enhance prevention, diagnosis, and treatment of HCV to reduce disease burden and ultimately eliminate HCV in Canada.http://dx.doi.org/10.1155/2016/7603526 |
| spellingShingle | Nicholas van Buuren Lorraine Fradette Jason Grebely Alexandra King Mel Krajden Sonya A. MacParland Alison Marshall Sahar Saeed Joyce Wilson Marina B. Klein Selena M. Sagan The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C Canadian Journal of Gastroenterology and Hepatology |
| title | The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
| title_full | The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
| title_fullStr | The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
| title_full_unstemmed | The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
| title_short | The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
| title_sort | 5th canadian symposium on hepatitis c virus we are not done yet remaining challenges in hepatitis c |
| url | http://dx.doi.org/10.1155/2016/7603526 |
| work_keys_str_mv | AT nicholasvanbuuren the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT lorrainefradette the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT jasongrebely the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT alexandraking the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT melkrajden the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT sonyaamacparland the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT alisonmarshall the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT saharsaeed the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT joycewilson the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT marinabklein the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT selenamsagan the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT nicholasvanbuuren 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT lorrainefradette 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT jasongrebely 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT alexandraking 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT melkrajden 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT sonyaamacparland 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT alisonmarshall 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT saharsaeed 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT joycewilson 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT marinabklein 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT selenamsagan 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc |